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Introduction
Extraordinary scientific progress made in the field of chronic 
myeloid leukemia (CML) led to the development of orally 
available tyrosine kinase inhibitors (TKIs), dramatically 
improving treatment results for patients with chronic-
phase CML (CP-CML).1,2 Imatinib (Gleevec®; Novartis, Basel, 
Switzerland) was the first TKI to obtain market authorization 
for the treatment of newly diagnosed patients; this was 
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A B S T R A C T
 
Treatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires 
full adherence in order to maximize the likelihood of achieving optimal responses, and 
to minimize healthcare costs. In this article, we review some of the methods available for 
assessing compliance, the main consequences of nonadherence on treatment outcomes, 
major factors commonly associated with poor compliance, a few successful measures for 
improving adherence and the most accepted recommendations for proactively managing 
adverse events.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by 
Elsevier Editora Ltda. All rights reserved. 
subsequently followed by the approval of dasatinib (Sprycel®; 
Bristol-Myers Squibb, Princeton, NJ, USA), and nilotinib 
(Tasigna®; Novartis, Basel, Switzerland), a highly potent 
second-generation TKI, adding the option of a second-line TKI 
therapy following imatinib resistance or intolerance.1,3
Despite these exciting new possibilities improving 
therapeutic outcomes in adults with CP-CML, a significant 
proportion of patients fail to take full advantage of the 
benefits of TKI therapy only because of poor adherence, 
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determined by socioeconomic factors and factors related to 
the healthcare system, the patient, the drug, and the disease. 
While oral agents engineered for cancer treatment are far more 
convenient for patients, and generally yield remarkable time 
and cost savings to the healthcare system, the optimization 
of treatment results eventually relies on adequate patient 
compliance to the prescribed therapy. This scenario highlights 
the importance of measuring, monitoring, and ensuring 
effective adherence to TKI treatment regimens, allowing CML 
patients to achieve the best possible outcomes.1,4-6
Due to the growing relevance of this theme, a review of 
the literature in PubMed was performed, using the keywords 
‘adherence’, and ‘CML treatment’.
Measuring adherence
Cancer patients are usually regarded as highly driven by the 
severity of their disease, and oncologists tend to presume 
that the patients will take the oral antineoplastic agents 
as prescribed. Nonetheless, nonadherence is a relatively 
common event during long-term treatment with TKIs, and as 
this phenomenon has been associated with worse outcomes, 
healthcare professionals should exclude this possibility 
before deciding on switching to next-line treatment in cases 
of unsatisfactory response. Several different methods are 
available to measure adherence to oral agents, even though 
all have flaws and limitations.7-9
Self-reporting, in which patients are requested to recollect 
how reliably they complied with their treatment regimen, 
has been criticized as too subjective, with a propensity for 
patients to over-report rates of adherence. In addition, some 
studies have surprisingly showed that adherent patients 
may sometimes report nonadherence. Although prospective 
patient diaries may also yield biased information regarding 
treatment compliance, they may be less influenced by recall 
bias on account of the supposed documentation after each 
dose taken.8-11
Pill counting, in which patients are required to return 
untaken pills for the calculation of missed doses, has been 
demonstrated to grossly overestimate adherence, mainly due 
to dumping of unused pills. Moreover, this method fails to 
provide information about compliance with dosing schedule. 
Pill counting is particularly subjected to bias; it becomes 
even less accurate when patients know that their pills will be 
counted.8,9,12,13
Measurement of serum drug levels is a method commonly 
thought to provide a less biased estimation of adherence. 
However, variations in individual pharmacokinetics, such as 
rates of drug absorption, distribution, metabolism, interactions 
and excretion, can significantly influence the assessment of 
adherence. Furthermore, non-adherent patients can still 
manipulate test results by taking extra doses of drug just 
before the exam, thereby giving the false impression that the 
patient is taking the drug correctly. Lastly, the costs of this test 
may be prohibitive for routine use outside the clinical research 
setting.8,9
Microelectronic Monitoring System (MEMS) is a newer 
method for assessing adherence that consists of an electronic 
device fitted into the cap of a regular looking drug bottle that 
electronically records every time the bottle cap is removed, 
and provides a computerized list of dates and times of bottle 
openings for several weeks. Because the system generates 
a good estimation of the number of doses taken daily, the 
number of missed or extra doses, and the dosing intervals, 
MEMS is often regarded as the gold standard to measure 
adherence; however, receiving a different bottle from the usual, 
as well as patient’s awareness of the system itself, may both 
be sources of bias. Besides, the act of opening a pill container 
does not necessarily imply that the patient actually took the 
drug as prescribed. MEMS is also significantly expensive, and 
hence used mainly for clinical research, rather than for large-
scale monitoring of patient populations.5,8,9
Pharmacy and medical records are also used to evaluate 
treatment compliance, possibly offering the most reliable 
estimation of actual drug use in large populations over a long 
period of time. With the Medication Possession Ratio method, 
adherence can be calculated as the amount of doses available 
to a subject in a given period, divided by the number of doses 
required for achieving full adherence to the treatment regimen 
during the same period of time. Although pharmacy or medical 
records avoid both recall bias and patient manipulation for 
social desirability, no information about dosing interval and 
schedule is provided since it is possible to miss doses, double 
up on pills, or even not take the drug at all, and still get 
prescriptions refilled on time.8,9
All methods present advantages and disadvantages that 
should be taken into account and the association of more 
than one method might improve the evaluation of treatment 
adherence. Therefore, even though measuring adherence is 
an essential step to ensure the highest likelihood of getting 
optimal results from TKI therapy for CP-CML patients, 
clinicians and the multidisciplinary team should be well 
aware of the strengths and weaknesses of each of the available 
methods used for this purpose and extreme caution should 
be exercised with the interpretation of data collected on 
treatment adherence.
Nonadherence and treatment outcomes
In general, it has been estimated that noncompliance with TKI 
therapy increases up to three times the risk for poor treatment 
outcomes of CP-CML patients.7
In a study using MEMS to measure adherence levels during 
a three-month period in 87 consecutive CP-CML patients who 
had received imatinib as first-line therapy, it was demonstrated 
that treatment adherence is a critical factor for achieving and 
maintaining molecular response in this group of patients. 
While median adherence was very high (98%) in this study, 
the probability of achieving major and complete molecular 
responses was significantly better in patients with more than 
90% of treatment adherence (28.4% vs. 94.5%; p-value < 0.001, 
and 0% vs. 43.8%; p-value = 0.002, respectively). In multivariate 
analysis, adherence was the only independent predictor for 
achieving complete molecular response.5
In a subsequent study, the probability of loss of complete 
cytogenetic response at two years was significantly higher 
in patients with an adherence rate of 85% or less (p-value = 
0.0001). An adherence rate of 85% or less (relative risk = 27.8; 
p-value = 0.002), and never having achieved a major molecular 
response (relative risk = 14.9; p-value = 0.01) were the only 
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independent predictors for loss of complete cytogenetic 
response and imatinib failure in the multivariate analysis.14
The Adherence Assessment with Glivec: Indicators and 
Outcomes (ADAGIO) study evaluated 169 CML patients using 
imatinib from 34 Belgium centers over a 90-day period. In this 
study, only 14.2% of all patients were found to be perfectly 
adherent to imatinib, while 71% took less than the prescribed 
dose and 14.8% took more. Patients with suboptimal response 
had significantly higher mean percentages of imatinib not 
taken (23.2%; standard deviation = 23.8) than did those with 
optimal response (7.3%; standard deviation = 19.3; p-value = 
0.005).7
Recently, several other studies assessed adherence to 
imatinib in the treatment of CML. In a retrospective analysis 
performed in India, using the Glivec International Patient 
Assistance Program (GIPAP) database, 29.6% of patients 
were found not completely adherent to imatinib and, in a 
multivariate analysis, nonadherence was the only factor 
significantly affecting event-free survival.15 On the other 
hand, few studies have evaluated adherence to second-line 
BCR-ABL TKIs. In a retrospective study published in 2012, 
patients receiving second-line nilotinib had poorer adherence, 
compared to patients taking dasatinib (100 mg once daily). 
No correlation was found between adherence and treatment 
response.16
In summary, nonadherence to TKI therapy in CML was 
correlated with poor therapeutic outcomes and increase of 
healthcare costs with these patients.17,18
Factors affecting treatment adherence
Adherence to oral anticancer treatment is a complex issue and 
a number of factors have been shown to predict nonadherence. 
The presence of depression, disbelief in the benefits of the 
drug, having to take other drugs for comorbidities, chronicity 
of disease, and length of treatment, are all important factors 
that may contribute to nonadherence in cancer patients.1,4 
In addition, TKIs Adverse Events (AEs), clinicians’ and site 
staff experience, practice behavior, and setting, and patients’ 
level of knowledge, were also all shown to have an impact 
on adherence.7 Furthermore, illiteracy, poor education, and 
lower cognitive level are factors that can restrict patients’ 
comprehension of the instructions given on treatment 
schedules and effects.6
The unavailability of appropriate home support is an 
additional source of increased likelihood of nonadherence, as 
changes in every-day activities can escalate tension with family 
and friends.19 Among the socioeconomic factors, although 
low economic status has not been considered an independent 
predictor of adherence, this status may induce patients to favor 
family needs over the best treatment available. In that regard, 
cancer treatment, particularly in elderly, usually demands 
substantial effort on the part of patients and caregivers, 
including many sacrifices in terms of economic resources to 
meet the cost of therapy.4 It has been shown that economic 
factors can indeed influence cancer patients’ decisions about 
their treatment,1,20 with those taking oral biologic agents being 
more inclined to restrict or discontinue doses when faced with 
situations of economic deprivation.1,20
Eliasson et al. found that longer duration of treatment, and 
having already achieved the expected therapeutic response, 
also tend to reduce adherence. Additionally, they explained 
that unintentional nonadherence generally refers to those 
situations when the patient may have wanted to take the drug 
but was unable to, either because of a personal cause, such as 
forgetting, or due to an external one, such as prescribing error, 
whereas intentional nonadherence refers to those situations 
in which the patient deliberately decides not to take the drugs 
as prescribed.19
More recently, the Italian Group for Adult Hematologic 
Diseases (GIMEMA) evaluated factors associated with 
adherence behavior in 413 CML patients receiving long-term 
therapy with imatinib. While 53% of patients reported optimal 
adherence, univariate analysis showed that concomitant drug 
burden and shorter time since achieving complete cytogenetic 
response were associated with better adherence (p-value 
= 0.019). In the multivariate analysis, higher level of social 
support, satisfaction with information received about the 
impact of disease and therapy, and concomitant drug burden 
were correlated with better adherence (p-value = 0.001, p-value 
= 0.001 and p-value = 0.006, respectively).21
Improving adherence
Although adequate compliance with BCR-ABL TKIs is 
critical to maximize treatment effectiveness and reduce the 
economic burden of disease among CML patients,18,21 many 
patients were found to ignore the fact that missing even a 
few doses of TKI therapy was likely to affect their response 
to treatment.1,11,18,19,22-24 A meta-analysis of adherence-
enhancing interventions found the highest impact for 
interventions combining educational and behavioral strategies 
versus each strategy alone.7 Therefore, chronic treatment with 
oral TKIs demands the use of new concepts and guidelines by 
healthcare professionals, in order to manage and follow-up 
CML patients. Improving treatment adherence for these 
patients will require appropriate access to information, 
an experienced multidisciplinary team, and continuous 
monitoring. Increased accessibility to pharmacists, behavioral 
specialists, and social workers, will enable the identification 
of causes for nonadherence,9,11,19 and the knowledge of these 
causes will allow the development of an action plan consistent 
with the needs of each individual patient. In this process, 
patient education about the disease and the treatment, as well 
as about prompt reporting of side effects, is indispensable to 
improve adherence.1,22
Managing adverse events
Therapy with BCR-ABL TKIs for CP-CML is generally well 
tolerated, although not completely free of side effects,3 and 
the occurrence of these side effects is associated with lower 
adherence.5 Recently updated clinical practice guidelines 
from the National Comprehensive Cancer Network (NCCN) 
provided specific recommendations for the management 
of AEs associated with imatinib, nilotinib, and dasatinib, in 
order to avoid compromising the clinical efficacy of these TKIs. 
Generally, grade 3/4 AEs are managed by dose interruption, 
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followed by resumption of treatment at a reduced dose after 
resolution of toxicity.25 Time to recovery for each individual 
patient is used to guide dosing decisions. Common mild 
or moderate AEs are managed with specific treatments or 
supportive care.1
Myelosuppression is observed in a significant proportion 
of CML patients treated with TKIs, especially among those 
with more advanced disease, and in those receiving dasatinib 
or nilotinib after previous imatinib treatment.3,22,26 In 
addition, a low incidence of bleeding events, usually related 
to the development of thrombocytopenia, has been reported 
with dasatinib.27 Thus, CML patients receiving TKI therapy 
should be educated to identify and immediately report fever, 
particularly in conjunction with infection, as well as easy 
bruising.22,27 Blood counts should be monitored weekly in 
the first month of treatment, monthly during Months 2 and 
3, and at every 3 months thereafter. Cytopenias are primarily 
managed by dose modification or interruption, and prescribing 
information for each BCR-ABL TKI describes the appropriate 
adjustments according to the intensity of these AEs.22 The 
use of growth factors, such as granulocyte colony-stimulating 
factor and recombinant human erythropoietin, has shown 
to allow continuous administration of TKI therapy without 
jeopardizing its antileukemic effect.3 Nonetheless, growth 
factors are not approved in this setting and recent guidelines 
do not support the use of erythropoietic-stimulating agents in 
myeloid malignancies.22
Peripheral edema is one of the most common AEs associated 
with BCR-ABL TKIs. Periorbital edema can be improved by 
elevating the head during sleep, and topical hydrocortisone 
or phenylephrine.3,22 Close electrolyte monitoring, restricted 
salt intake, administration of low-dose loop diuretics such as 
furosemide, and eventual supplementation of potassium and 
magnesium, have all proved to be helpful in the management 
of moderate edema. More severe cases may require treatment 
interruption and, in some cases, surgery.3
Pleural effusion is an extremely rare complication of TKI 
therapy for CML.3 However, all patients, particularly those 
with risk factors, should be educated about shortness of 
breath, and should be monitored closely for symptoms 
suggestive of fluid retention, including regular assessment 
of body weight, heart- and lung-associated symptoms, and 
peripheral tissue tone. Rapid weight gain should prompt 
immediate investigation.22, 27 Although the administration of 
pulse steroids, in addition to treatment interruption, has been 
associated with faster resolution of the pleural effusion, part of 
the beneficial effect might be related to the sudden decrease in 
TKI levels. Large recurrent effusions may require thoracentesis, 
a temporary pleuroperitoneal shunt, and/or pleurodesis. After 
resolution of the effusion, therapy usually can be resumed at 
a reduced dose.3
Skin toxicity, generally characterized by maculopapular 
rash, has been reported during TKI therapy in CML patients. 
Symptoms are usually mild and self-limiting, allowing 
treatment continuation.3,22  For the minority of patients 
requiring interventions, antihistamines, short courses of 
steroids, and topical triamcinolone acetonide ointment may 
hasten the palliation of symptoms.26 Rare cases of Stevens-
Johnson syndrome mandates immediate interruption of TKI 
treatment and administration of systemic steroid therapy.3
A low proportion of CML patients can experience 
gastrointestinal AEs during TKI therapy. Usually, there is a 
continuous increase in the frequency of bowel movements 
during the initial treatment phase of treatment, rarely 
progressing to diarrhea symptoms. Bowel function tends 
to return to normal after a few weeks.26 Reduction in 
gastrointestinal symptoms has been associated with the 
ingestion of BCR-ABL TKIs with water and large meals, except 
for nilotinib, which requires fasting for its administration.22 
Although seldom necessary, anti-emetic and anti-diarrheal 
drugs can be used for the management of gastrointestinal 
AEs, permitting treatment continuation without reductions 
or interruptions.26
Altered levels of liver enzymes have been frequently 
reported in CML patients treated with TKIs, usually requiring 
measurement of liver function at baseline, every week for 
the first month and every 3 months thereafter. Patients 
should be advised to refrain from drinking alcohol or taking 
any hepatotoxic drug. Mild abnormalities generally allow 
continuation of TKI therapy under careful monitoring. 
Treatment should be interrupted in case of grade 3/4 toxicity, 
but dose can be resumed at the same level after improvement of 
liver function. Treatment should be permanently discontinued 
in case of recurrent serious toxicity.3 Pancreatic abnormalities 
have been reported during nilotinib therapy; therefore, caution 
is advised when using nilotinib in patients with a history of 
pancreatitis. Lipase levels should be monitored in these 
cases.22
Muscular spasms and muscle pain have also been 
associated with TKI therapy. Relief of cramps can be obtained 
with calcium and magnesium supplements or quinine. Non-
steroidal anti-inflammatory drugs may help to relieve mild 
pain in patients with adequate platelet counts and no prior 
gastrointestinal bleeding.22,26
Cardiotoxicity is an infrequent, but potentially life-
threatening complication of BCR-ABL TKIs. Since abnormalities 
in mineral metabolism, including hypophosphatemia, 
hypokalemia, hyperkalemia, hyponatremia and hypocalcemia, 
have been reported with all BCR-ABL TKIs, electrolyte levels 
should be corrected before therapy and periodically monitored 
during therapy, thus preventing negative effects on cardiac 
function. In addition, strong CYP3A4 inhibitors should be used 
with caution during imatinib treatment, and should be avoided 
during nilotinib and dasatinib therapy.22 The management of 
cardiac AEs generally includes treatment discontinuation, 
echocardiographic monitoring, and aggressive therapy with 
diuretics, angiotensin-converting enzyme inhibitors, and beta 
blockers.3
Conclusion
A highly specialized and well-trained multidisciplinary team 
that is capable of gaining the trust of patients and improving 
long-term treatment adherence is of utmost importance for 
the treatment of CP-CML patients in the modern era. Collecting 
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specific information about factors that affect treatment 
adherence is necessary, and establishing an individualized 
approach to these patients is strongly advised.
Although BCR-ABL TKIs have revolutionized the treatment 
of CP-CML, monitoring and ensuring adherence to these 
agents is an essential step for achieving optimal responses 
and for decreasing the economic burden of the disease. 
Patient education programs, devices with reminder function, 
strong family support, a solid patient-physician relationship, 
periodic telephone counseling, and proactive management of 
AEs, are all initiatives that may help to increase compliance to 
treatment, and should therefore be considered for all patients 
receiving BCR-ABL TKIs for the treatment of CP-CML.
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